Gc-MAF injections may support immune defense.
For almost 20 years, Nobuto Yamamoto, director of the Division of Cancer Immunology and Molecular Biology at Socrates Institute for Therapeutic Immunology (Philadelphia, Pennsylvania), has been studying the effect of directly administering GcMAF to cancer patients, thereby bypassing the malignant cells' NaGalase defense. Yamamoto has used Gc-MAF injections (100 nanograms once a week) "on a variety of cancers ... [including] prostate, breast, colon, stomach, liver, lung, kidney, bladder, uterus, ovary, head/neck, melanoma, and fibrosarcoma." Undifferentiated tumor cells, such as breast and prostate adenocarcinomas, respond more quickly to Gc-MAC injections than well-differentiated cancer cells, such as those found in squamous carcinomas. In a 2008 study with 16 breast cancer patients, NaGalase enzyme fell to levels found in healthy people after 16 to 22 weekly doses of Gc-MAC. In contrast, it took over 75 weekly doses before NaGalase reached healthy levels in people with well-differentiated head/neck tumors. Treatment appears to be long lasting. A 2008 study with 16 prostate cancer patients found no increase in serum NaGalase during the seven years of observation after Gc-MAC treatment. Annual computed tomographic scans also found no evidence of prostate cancer in these men.
A PubMed search locates numerous studies involving vitamin D binding protein-macrophage activating factor (DBP-maf) and Gc-macrophage activating factor. In an animal study performed by Oliver Kisker et al., DBP-maf was isolated from a human pancreatic cancer cell line. (It appears that the tumor uses DBP-maf to prevent secondary tumors.) DBP-maf may have antiangiogenic properties in addition to macrophage activating properties, according Kisker and colleagues. Yamamoto and colleagues treated purified Gc protein with immobilized [beta]-galactosidase and sialidase to make the Gc-MAF used in their studies. Their manufacturing process is patent protected. Gc-MAF itself is not patentable because it is a natural compound. Despite the positive studies, Bill Sardi and Timothy Hubbell report: "There is no evidence of any current effort to commercialize this therapy or put it into practice."
Kisker O, Onizuka S, Becker CM, Fannon M, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia. January 2003;5(1):32-40. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC1502120/pdf/neo0501_0032.pdf. Accessed June 16, 2010.
Sardi B, Hubbell T. Real help for cancer? [Web article]. LewRockwell.com. May 22, 2008. http://www.lewrockwell.com/sardi/sardi84.htmt. Accessed June 16, 2010.
Yamamoto N, Suyma H, Yamamoto N. Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Transl Oncol. June 2008:1(2):65-72, Available at: www.transonc.com/pdf/manuscript/v01i02/neo08106.pdf. Accessed June 16, 2010.
briefed by Jule Klotter
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 1, 2010|
|Previous Article:||Film documents cancer 'warriors' survival.|
|Next Article:||Homeopathic treatment helps some cancers.|